EGFR exon 20 insertions are among the rarer EGFR mutations (approximately 9% of EGFR-mutant NSCLC patients) and treatment for these mutations remain elusive without an approved inhibitor32,33. Here, EGFR is linked to non-small cell lung carcinoma.